SWITZERLAND

Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe

Retrieved on: 
Monday, September 16, 2024

Atamyo CEO Stephan Degove will provide a corporate overview at Sach’s 20th Annual Biotech in Europe Forum, Chardan's 8th Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa 2024.

Key Points: 
  • Atamyo CEO Stephan Degove will provide a corporate overview at Sach’s 20th Annual Biotech in Europe Forum, Chardan's 8th Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa 2024.
  • Sach’s 20th Annual Biotech in Europe Forum, held in Basel, Switzerland, on September 25-26, 2024:
    Presentation on September 25, at 11:40 am (CEST), in the Ruby Room.
  • Both posters will be presented during Poster Session II on Wednesday 23 October, 1:30 pm to 3 pm (CEST).
  • Atamyo has rights to the LICA-1 capsid for cardiomyopathies indications.

Covid-19 may lead to longest period of peacetime excess mortality, says new Swiss Re report

Retrieved on: 
Monday, September 16, 2024

[1] If this continues, our analysis suggests a potential scenario of elevated excess mortality extending over the next decade.

Key Points: 
  • [1] If this continues, our analysis suggests a potential scenario of elevated excess mortality extending over the next decade.
  • Excess mortality is a measure of the number of deaths above an expected level in a given population.
  • Typically, all-cause excess mortality should be around zero, as the major causes of death remain relatively stable over the long-term baseline assumption.
  • Swiss Re's report examines an optimistic scenario where excess mortality rates return to pre-pandemic levels as early as 2028.

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe

Retrieved on: 
Monday, September 16, 2024

(NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for the latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7.

Key Points: 
  • (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for the latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7.
  • "With quicker procedures and more efficient clot removal, we have improved outcomes while demonstrating a high level of safety.
  • Lightning Flash 2.0 and Lightning Bolt 7 come on the heels of Penumbra recently receiving CE Mark for five of its stroke reperfusion and access catheters, expanding both its neuro and vascular portfolios in Europe.
  • These latest innovations provide physicians in Europe with a robust selection of devices to remove blood clots throughout the body.

Curatis: Significantly Increased Sales in Core Business and Projects in Development Pipeline on Track

Retrieved on: 
Monday, September 16, 2024

In the distribution business, the aim is to increase sales by securing additional drugs for distribution in Switzerland and expanding the distribution business geographically to key European markets.

Key Points: 
  • In the distribution business, the aim is to increase sales by securing additional drugs for distribution in Switzerland and expanding the distribution business geographically to key European markets.
  • Curatis is focusing its development activities for C-PTBE-01 on an extremely rare group of aggressive brain tumours (Diffuse Midline Glioma, DMG).
  • In connection with DMG, indirect brain damage regularly occurs due to an accumulation of extracellular fluid in the vicinity of the tumour.
  • C-AM-01 is currently in Phase IIa and the next development step for C-AM-01 is a Phase IIb dose-finding clinical trial.

Remedee Labs' Solution becomes the first CE marked medical device (class IIa) approved for the treatment of fibromyalgia in Europe

Retrieved on: 
Monday, September 16, 2024

The Remedee Labs solution is now the first medical device clinically validated and certified in Europe to provide symptom relief for fibromyalgia, a disorder for which no specific treatment had previously been identified.

Key Points: 
  • The Remedee Labs solution is now the first medical device clinically validated and certified in Europe to provide symptom relief for fibromyalgia, a disorder for which no specific treatment had previously been identified.
  • This achievement marks a major advance in care for the millions of patients suffering from fibromyalgia.
  • Remedee Labs' solution for patients with fibromyalgia has also been recognized in the United States, where it received Breakthrough Device Designation from the Food & Drug Administration (FDA) in 2022.
  • Remedee Labs will launch its dedicated medical offer for fibromyalgia patients on the French market in 2025.

What is a trained clown and what does the training look like?

Retrieved on: 
Sunday, September 15, 2024

In real life, however, they often come from clown schools, theatre institutes or universities.

Key Points: 
  • In real life, however, they often come from clown schools, theatre institutes or universities.
  • So, how are they trained and what are some of the main institutions?

We’ve always had clowns

  • Clowns are often afforded special privilege to say or do what would be unthinkable for most of us.
  • Clowns also appear in the literature on ancient Greece and ancient Rome, again enjoying positions of relative privilege at the time.
  • Today’s clowns may be entertainers, political activists, boundary-pushers, or even medical clowns performing to relieve people’s physical and emotional pain in hospitals or aged care settings.

How are clowns trained?

  • The methods, techniques and schools of clowning are as diverse as the cultural history of clowns itself.
  • Not surprisingly, many circuses train clowns.
  • In fact, there are clown and physical theatre hubs all around the world that train clowns.
  • All of these approaches help future clowns develop their artistic and expressive pathways by combining technical skills with personal artistic sensibilities.

How purpose shapes training

  • If you want to become a circus clown, your training may include classical acting techniques, interdisciplinary circus arts and dance, physical comedy, acrobatics, yoga, stage combat, juggling and storytelling.
  • One medical clowning organisation, Dream Doctors, says that after inital training, their graduates undertake about 200 hours of ongoing professional development seminars, courses and workshops every year.

Clowns master the body as a storyteller

  • Trained clowns create engaging experiences for audiences, generate memorable moments and harness the power of creativity for wellbeing and social change.
  • Trained clowns master the body as a storyteller, fostering new artistic creation and stimulating creative intelligence.

The 3rd International Summit for Mayors of Rural Tourism Villages & the Forum of Best Tourism Villages is Coming to Huangling, Wuyuan

Retrieved on: 
Sunday, September 15, 2024

The UN Tourism launched the programmes of 'Best Tourism Village' in 2021 to honor outstanding examples of rural tourism destinations that feature with distinctive cultural and natural resources.

Key Points: 
  • The UN Tourism launched the programmes of 'Best Tourism Village' in 2021 to honor outstanding examples of rural tourism destinations that feature with distinctive cultural and natural resources.
  • So far, 129 villages worldwide have been recognized as the Best Tourism Villages, out of which eight are China's villages, including Huangling Village.
  • The 3rd International Summit for Mayors of Rural Tourism Villages features more participants from various cultural and geographic background.
  • Since the first International Summit for Mayors of Rural Tourism Villages was held in Huangling Village, Wuyuan, Jiangxi Province, in October 2018, the Summit has continuously promoted interaction and communication among the domestic and international rural tourism destinations over the past six years.

Global AI Summit Calls for Global Action to Guarantee AI Innovation is for the "Good of Humanity"

Retrieved on: 
Saturday, September 14, 2024

The live stream of the summit, organized by the Saudi Data and AI Authority (SDAIA), received 3.7m views.

Key Points: 
  • The live stream of the summit, organized by the Saudi Data and AI Authority (SDAIA), received 3.7m views.
  • It also witnessed over 25 launches and announcements, and facilitated the signing of over 80 agreements and Memoranda of Understanding (MoUs).
  • The key output from the summit was the need for governments and policy makers to take global action to ensure that AI technology evolves for the good of humanity.
  • The success of GAIN 2024 ensures that the Kingdom's AI infrastructure will be significantly strengthened and has cemented Saudi Arabia position at the center of global AI.

Global AI Summit Calls for Global Action to Guarantee AI Innovation is for the "Good of Humanity"

Retrieved on: 
Saturday, September 14, 2024

The live stream of the summit, organized by the Saudi Data and AI Authority (SDAIA), received 3.7m views.

Key Points: 
  • The live stream of the summit, organized by the Saudi Data and AI Authority (SDAIA), received 3.7m views.
  • It also witnessed over 25 launches and announcements, and facilitated the signing of over 80 agreements and Memoranda of Understanding (MoUs).
  • The key output from the summit was the need for governments and policy makers to take global action to ensure that AI technology evolves for the good of humanity.
  • The success of GAIN 2024 ensures that the Kingdom's AI infrastructure will be significantly strengthened and has cemented Saudi Arabia position at the center of global AI.

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Retrieved on: 
Saturday, September 14, 2024

BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024.
  • The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616).
  • The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on LinkedIn .